Our data provide the first bmx preclinical trial supporting BMD drug development and give new insights into the potential for dissociative steroids such as vamorolone to more broadly treat muscle diseases with chronic inflammation, cardiomyopathy, alternative dystrophin isoforms, or reduced dystrophin. Here, DMD is linked to cardiomyopathy.